查看文章

Recent years have seen new developments, mostly therapeutic, in the perioperative management of antiplatelet drugs (AA). Two P2Y 12 receptor antagonists, prasugrel and ticagrelor, have now been incorporated into the treatment of coronary syndrome. Two others, cangrelor and vorapaxar, have been approved by health authorities in the United States and Europe, and may soon be available in Spain.

One of the most persistent recommendations in the “Practice guideline for the preoperative management of platelet aggregation antagonists in non-cardiac surgery” 1 was the need to maintain aspirin treatment for secondary prophylaxis of thrombotic disease. The findings of the POISE-2 study (Perioperative Ischaemic Evaluation 2) cast doubt on this recommendation, and sparked an interesting debate on the need to maintain or withdraw aspirin in patients scheduled for non-cardiac surgery. 2